Key Highlights

  • Third-quarter 2026 net loss was USD 10.1 million, or USD 0.05 per share.
  • Research and development expenses were USD 7.0 million, against USD 4.2 million.
  • Cash and cash equivalents were USD 134.7 million at September 30, 2026.
  • Warrant exercises provided approximately USD 85.1 million during the nine months.

SELLAS Life Sciences (NASDAQ:SLS) reported a third-quarter 2026 net loss of USD 10.1 million, or USD 0.05 per share, in line with an estimate of a loss of USD 0.05 per share. The late-stage clinical biopharmaceutical company, which trades on the Nasdaq Stock Market, focuses on novel cancer therapeutics and reported no revenue.

Its lead candidate is galinpepimut-S, or GPS, a cancer immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms Tumor 1 protein. Its second candidate is SLS009, a CDK9 inhibitor licensed from GenFleet Therapeutics.

Operating Results

Research and development expenses were USD 7,029 thousand, against USD 4,216 thousand. The filing says the increase of approximately USD 2.8 million was primarily attributable to USD 1.7 million of higher external clinical trial expenses for SLS009, driven by the timing of enrollment in its randomized Phase 2 trial in newly diagnosed first-line acute myeloid leukemia patients, and USD 1.3 million of higher clinical and regulatory consulting costs as it prepares for a potential BLA filing for GPS following the final analysis of the REGAL study.

General and administrative expenses were USD 4.3 million, against USD 2.9 million. Total operating expenses were USD 11,309 thousand, against USD 7,083 thousand, and loss from operations was the same USD 11,309 thousand, against USD 7,083 thousand.

Interest income was USD 1,218 thousand, against USD 292 thousand. Net loss was USD 10,091 thousand, against USD 6,791 thousand, or USD 0.05 per basic and diluted share, against USD 0.06. Weighted-average shares were 202,437,078, against 108,396,260.

For the nine months, Research and Development expenses were USD 18,430 thousand, against USD 11,292 thousand, and general and administrative expenses were USD 12,760 thousand, against USD 8,727 thousand. Net loss was USD 28,103 thousand, or USD 0.15 per share, against USD 19,205 thousand, or USD 0.20.

Spending by Program

The filing breaks out third-quarter external clinical trial expenses of USD 991 thousand for GPS, against USD 1,239 thousand, and USD 2,651 thousand for SLS009, against USD 952 thousand. Clinical and regulatory consulting costs were USD 1,869 thousand, against USD 597 thousand. Employee-related expenses were USD 783 thousand, against USD 757 thousand, and stock-based compensation was USD 243 thousand, against USD 110 thousand. Manufacturing and clinical drug Supply costs were USD 307 thousand, against USD 386 thousand.

Liquidity and Financing

At September 30, 2026, the company had cash and cash equivalents of USD 134.7 million, restricted cash of USD 0.1 million and an accumulated Deficit of USD 303.1 million. Total Assets were USD 141,091 thousand and total stockholders' Equity was USD 131,805 thousand.

During the nine months, the company received approximately USD 85.1 million from the exercise of 50.4 million outstanding warrants at a weighted average exercise price of USD 1.69 per share. Net cash provided by financing activities was USD 85.3 million, including approximately USD 0.2 million from employee stock purchase plan purchases. In March 2026, the company entered into a sales agreement with TD Securities (USA) LLC to sell shares of its common stock.

Management states that its cash and cash equivalents are sufficient to fund current planned operations for at least the next twelve months from the date of issuance of the financial statements. It adds that it may pursue additional Capital through equity or debt financings, license agreements or collaborations, that its expectations rest on estimates subject to risks and uncertainties, and that it may need to seek financing opportunities sooner if actual results differ.